Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, on July 16, 2019. The filing reports on corporate developments occurring during the month of July 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change announced is the dual listing of Enlivex's ordinary shares on the Tel Aviv Stock Exchange (TASE), effective July 22, 2019, under the symbol ENLV. The company's shares will continue to trade on the NASDAQ Capital Market.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors. It solely references a press release (Exhibit 99.1) regarding the stock exchange listing.
Investor Verification Checklist
- Verify the effective date of the TASE listing (July 22, 2019).
- Confirm the trading symbol on the Tel Aviv Stock Exchange (ENLV).
- Review the full press release (Exhibit 99.1) for details on the listing process.
- Check subsequent filings for any financial impact of the dual listing.